|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Termine JD, Kleinman HK, Whitson SW, Conn
KM, McGarvey ML and Martin GR: Osteonectin, a bone-specific protein
linking mineral to collagen. Cell. 26:99–105. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mann K, Deutzmann R, Paulsson M and Timpl
R: Solubilization of protein BM-40 from a basement membrane tumor
with chelating agents and evidence for its identity with
osteonectin and SPARC. FEBS Lett. 218:167–172. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagaraju GP and Sharma D: Anti-cancer role
of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev.
37:559–566. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guweidhi A, Kleeff J, Adwan H, Giese NA,
Wente MN, Giese T, Büchler MW, Berger MR and Friess H: Osteonectin
influences growth and invasion of pancreatic cancer cells. Ann
Surg. 242:224–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bornstein P and Sage EH: Matricellular
proteins: Extracellular modulators of cell function. Curr Opin Cell
Biol. 14:608–616. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Podhajcer OL, Benedetti LG, Girotti MR,
Prada F, Salvatierra E and Llera AS: The role of the matricellular
protein SPARC in the dynamic interaction between the tumor and the
host. Cancer Metastasis Rev. 27:691–705. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang
KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different
histologic types and its role in the outcome of invasive ductal
carcinoma. Breast J. 16:305–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomas R, True LD, Bassuk JA, Lange PH and
Vessella RL: Differential expression of osteonectin/SPARC during
human prostate cancer progression. Clin Cancer Res. 6:1140–1149.
2000.PubMed/NCBI
|
|
12
|
Chan SK, Griffith OL, Tai IT and Jones SJ:
Meta-analysis of colorectal cancer gene expression profiling
studies identifies consistently reported candidate biomarkers.
Cancer Epidemiol Biomarkers Prev. 17:543–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Franke K, Carl-McGrath S, Röhl FW,
Lendeckel U, Ebert MP, Tänzer M, Pross M and Röcken C: Differential
expression of SPARC in intestinal-type gastric cancer correlates
with tumor progression and nodal spread. Transl Oncol. 2:310–320.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ledda F, Bravo AI, Adris S, Bover L,
Mordoh J and Podhajcer OL: The expression of the secreted protein
acidic and rich in cysteine (SPARC) is associated with the
neoplastic progression of human melanoma. J Invest Dermatol.
108:210–214. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rempel SA, Golembieski WA, Ge S, Lemke N,
Elisevich K, Mikkelsen T and Gutiérrez JA: SPARC: A signal of
astrocytic neoplastic transformation and reactive response in human
primary and xenograft gliomas. J Neuropathol Exp Neurol.
57:1112–1121. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao
HQ: SPARC is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 16:260–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Yang M, Shan L, Qi L, Chai C, Zhou
Q, Yao K, Wu H and Sun W: The role of SPARC protein expression in
the progress of gastric cancer. Pathol Oncol Res. 18:697–702. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC International Union Against Cancer: TNM Classification of
Malignant Tumours. 7th edition. Wiley-Blackwell; Chichester, West
Sussex, UK: 2009
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mazumdar M, Smith A and Bacik J: Methods
for categorizing a prognostic variable in a multivariable setting.
Stat Med. 22:559–571. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maeng HY, Song SB, Choi DK, Kim KE, Jeong
HY, Sakaki Y and Furihata C: Osteonectin-expressing cells in human
stomach cancer and their possible clinical significance. Cancer
Lett. 184:117–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koukourakis MI, Giatromanolaki A, Brekken
RA, Sivridis E, Gatter KC, Harris AL and Sage EH: Enhanced
expression of SPARC/osteonectin in the tumor-associated stroma of
non-small cell lung cancer is correlated with markers of
hypoxia/acidity and with poor prognosis of patients. Cancer Res.
63:5376–5380. 2003.PubMed/NCBI
|
|
23
|
Infante JR, Matsubayashi H, Sato N,
Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and
Goggins M: Peritumoral fibroblast SPARC expression and patient
outcome with resectable pancreatic adenocarcinoma. J Clin Oncol.
25:319–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB,
Yang WI, Roh JK, Noh SH and Chung HC: A randomized phase 2 study of
docetaxel and S-1 versus docetaxel and cisplatin in advanced
gastric cancer with an evaluation of SPARC expression for
personalized therapy. Cancer. 117:2050–2057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato T, Oshima T, Yamamoto N, Yamada T,
Hasegawa S, Yukawa N, Numata K, Kunisaki C, Tanaka K, Shiozawa M,
et al: Clinical significance of SPARC gene expression in patients
with gastric cancer. J Surg Oncol. 108:364–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamashita K, Upadhay S, Mimori K, Inoue H
and Mori M: Clinical significance of secreted protein acidic and
rich in cystein in esophageal carcinoma and its relation to
carcinoma progression. Cancer. 97:2412–2419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McClung HM, Thomas SL, Osenkowski P, Toth
M, Menon P, Raz A, Fridman R and Rempel SA: SPARC upregulates
MT1-MMP expression, MMP-2 activation, and the secretion and
cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett.
419:172–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weaver MS, Workman G and Sage EH: The
copper binding domain of SPARC mediates cell survival in vitro via
interaction with integrin beta1 and activation of integrin-linked
kinase. J Biol Chem. 283:22826–22837. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huynh MH, Sodek K, Lee H and Ringuette M:
Interaction between SPARC and tubulin in Xenopus. Cell Tissue Res.
317:313–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desai NP, Trieu V, Hwang LY, Wu R,
Soon-Shiong P and Gradishar WJ: Improved effectiveness of
nanoparticle albumin-bound (nab) paclitaxel versus
polysorbate-based docetaxel in multiple xenografts as a function of
HER2 and SPARC status. Anticancer Drugs. 19:899–909. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gradishar WJ: Albumin-bound paclitaxel: A
next-generation taxane. Expert Opin Pharmacother. 7:1041–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
